X4 Pharmaceuticals Inc. Common Stock (XFOR)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable economics and a margin of safety. X4 is a 45-employee rare-disease biotech. Revenue grew from $2.6M in FY2024, period ended 2024-12-31, to $35.1M in FY2025, period ended 2025-12-31, and fiscal Q2 2026, the quarter ended 2026-06-30, had $8.8M revenue, so there is commercial traction. But it still lost $16.2M in that quarter and $79.2M in FY2025, period ended 2025-12-31. Trailing free cash flow was -$88.7M, a -34.4% FCF yield, so it consumes cash. ROE is -113.08%, ROCE -28.15%, Altman Z -1.14, Piotroski 4/9, and debt/equity 0.50. These are not the marks of a fortress. Does it have a moat? A single rare-disease drug and a 45-person operation may have some orphan-drug pricing power, but no demonstrated durable profitability, and clinical and commercial risk remain. At $2.60 on 2026-10-13, FairStock's Graham Number is $7.22 and margin of safety is 63.99%, while P/B is 1.60. The FairStock P/E of 1.82 is not meaningful against filed losses; PEG 0.05 also rests on uncertain future growth. FairStock score is 56/100, and the Lynch category is none because of losses in each of the last 4 years. The price may look statistically cheap, but without positive free cash flow and with a negative Altman Z, the apparent discount is speculative. Revenue growth is encouraging, yet losses widened from FY2024, period ended 2024-12-31, to FY2025, period ended 2025-12-31. I would need evidence of a path to profitability before calling this a value opportunity rather than a lottery ticket.

In plain English: X4 Pharmaceuticals is a small biotech focused on rare immune-system diseases. It is losing money and burning cash, so the business looks financially weak even though sales are growing. The share price looks cheaper than several accounting measures, but the losses make that cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer